For research use only. Not for therapeutic Use.
Mevociclib（Cat No.:I018982）is a selective inhibitor of cyclin-dependent kinases (CDKs), particularly targeting CDK4 and CDK6, which play crucial roles in regulating the cell cycle. By inhibiting these kinases, Mevociclib disrupts cell proliferation, making it a potential therapeutic agent in the treatment of various cancers, especially those driven by abnormal CDK activity. Preclinical studies indicate that Mevociclib may enhance the effectiveness of other anticancer treatments by targeting tumor growth pathways. Ongoing research is focused on its efficacy and safety in clinical settings, aiming to position it as a valuable option in oncology.
| Catalog Number | I018982 |
| CAS Number | 1816989-16-8 |
| Molecular Formula | C₃₁H₃₅ClN₈O₂ |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-1-methylcyclohexyl]-5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridine-2-carboxamide |
| InChI | InChI=1S/C31H35ClN8O2/c1-31(39-29(42)26-13-12-21(17-33-26)36-27(41)11-7-15-40(2)3)14-6-8-20(16-31)37-30-35-19-24(32)28(38-30)23-18-34-25-10-5-4-9-22(23)25/h4-5,7,9-13,17-20,34H,6,8,14-16H2,1-3H3,(H,36,41)(H,39,42)(H,35,37,38)/b11-7+/t20-,31+/m1/s1 |
| InChIKey | SCJNYBYSTCRPAO-LXBQGUBHSA-N |
| SMILES | CC1(CCCC(C1)NC2=NC=C(C(=N2)C3=CNC4=CC=CC=C43)Cl)NC(=O)C5=NC=C(C=C5)NC(=O)C=CCN(C)C |
| Reference | [1]. Hu S, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 2019 May 7.<br>[2]. Shanhu Hu, et al. SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors. |
